Neutralisation of IL12 p40 or IL23 p40 does not block inflammation in multiple sclerosis

The Lancet Neurology

Volumn 7, Issue 9, 2008, Pages 765-766

  Martin, Roland ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOLOGIC AGENT; INTERLEUKIN 12P40; INTERLEUKIN 23; INTERLEUKIN 23P40; UNCLASSIFIED DRUG; USTEKINUMAB;

BLOOD BRAIN BARRIER; CELL DIFFERENTIATION; CLINICAL TRIAL; GENE MUTATION; HUMAN; INFLAMMATION; LETTER; MULTIPLE SCLEROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; T LYMPHOCYTE; TH1 CELL; TH17 CELL;

ANTIBODIES, MONOCLONAL; BRAIN; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATION; INTERLEUKIN-12; INTERLEUKIN-23; MULTIPLE SCLEROSIS; T-LYMPHOCYTES; TREATMENT FAILURE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 48849089330     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(08)70174-1     Document Type: Letter

References (9)

1. McFarland H.F., and Martin R. Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol 8 (2007) 913-919
2. Kikly K., Liu L., Na S., and Sedgwick J.D. The IL-23/Th(17) axis: therapeutic targets for autoimmune inflammation. Curr Opin Immunol 18 (2006) 670-675
3. Hunter C.A. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat Rev Immunol 5 (2005) 521-531
4. 't Hart B.A., Brok H.P.M., Remarque E., et al. Suppression of ongoing disease in a nonhuman primate model of multiple sclerosis by a human-anti-human IL-12p40 antibody. J Immunol 175 (2005) 4761-4768
5. Cua D.J., Sherlock J., Chen Y., et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421 (2003) 744-748
6. Segal B.M., Constantinescu C.S., Raychaudhuri A., et al. Repeated subcutaneous injections of IL12p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised dose-ranging study. Lancet Neurol 7 (2008) 796-804
7. Bailey S.L., Schreiner B., McMahon E.J., and Miller S.D. CNS myeloid DCs presenting endogenous myelin peptides preferentially' polarize CD4+ T(H)-17 cells in relapsing EAE. Nat Immunol 8 (2007) 172-180
8. Becher B., Durell B.G., and Noelle R.J. IL-23 produced by CNS-resident cells controls T-cell encephalitogenicity during the effector phase of experimental autoimmune encephalomyelitis. J Clin Invest 112 (2003) 1186-1191
9. Leonardi C.L., Kimball A.B., Papp K.A., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371 (2008) 1665-1674